About Ray Therapeutics
Ray Therapeutics is a private company based in San Francisco, California, incorporated in 2021 in Delaware. It has reported $19,999,986 raised in two offerings on Form D since April 2022. Its chief executive is Paul Bresge.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 15, 2023 | May 26, 2023 | $13,999,986of $99.9M target | 13 | $1.0M | EquityRule 506(b) | Form D ↗ |
| May 25, 2021 | Apr 5, 2022 | $6,000,000fully sold | 15 | $400K | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $19,999,986 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Ray Therapeutics's Form D filed May 26, 2023.
TA
Tiba Aynechi
Director
DK
Dmitry Kuzmin
Director
SA
Sean Ainsworth
Executive officer and director
RC
Raymond Camahort
Director
HC
Hannah Chang
Director
GA
Gary Abrams
Director
PB
Paul Bresge
Chief Executive Officer and director
Earlier filings also listed Cameron Gallagher (director, last listed Apr 2022) and Andrew Howard (executive officer, last listed Apr 2022).